Abstract

BackgroundAbatacept (ABT), a selective T-cell co-stimulation modulator, is a new biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. We have previously reported that...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0377 Differences in Baseline Predictive Factors for Remission at 52 Weeks by Concomitant MTX Use during Tocilizumab Treatment Using Propensity Score Matched Groups
Y Kanayama ... S Asai
Annals of the Rheumatic Diseases | VOL. 75
Y Kanayama, et. al.Y Kanayama ... S Asai
01 Jun 2016
Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis.
Henrik Svanström ... Mads Melbye
Pharmacoepidemiology and drug safety | VOL. 27
Henrik Svanström, et. al.Henrik Svanström ... Mads Melbye
24 May 2018
AB0945 Secukinumab efficacy in patients with active psoriatic arthritis: pooled analysis of four phase 3 trials by prior anti-tnf therapy and concomitant methotrexate use
K Abrams ... B Kirkham
Annals of the Rheumatic Diseases | VOL. 77
K Abrams, et. al.K Abrams ... B Kirkham
01 Jun 2018
Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
Paulo Reis ... Eric M Ruderman
Rheumatology and therapy | VOL. 7
Paulo Reis, et. al.Paulo Reis ... Eric M Ruderman
16 Nov 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers